Core Points - Pharming Group N.V. announced the adoption of all proposals at the Extraordinary General Meeting of Shareholders, including the appointment of Mr. Fabrice Chouraqui as Executive Director and CEO for a four-year term [1][2] - Mr. Chouraqui succeeds Mr. Sijmen de Vries, who will remain as a strategic advisor until December 31, 2025, to ensure a smooth transition [2] - The remuneration package for Mr. Chouraqui was also approved by shareholders [2] Company Overview - Pharming Group N.V. is a global biopharmaceutical company focused on transforming the lives of patients with rare and life-threatening diseases [5] - The company is engaged in the commercialization and development of protein replacement therapies and precision medicines, including small molecules and biologics [5] - Pharming is headquartered in Leiden, the Netherlands, and operates in over 30 markets across North America, Europe, the Middle East, Africa, and Asia-Pacific [5] Leadership Commentary - Dr. Richard Peters, Chairman of the Board, expressed a warm welcome to Mr. Chouraqui and acknowledged the significant contributions of the outgoing CEO, Mr. de Vries, over the past 16 years [4]
Pharming Group reports on results of the 2025 Extraordinary General Meeting of Shareholders